No label defined (Q3155555)

From EU Knowledge Graph
Revision as of 15:25, 12 October 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): Diabetic nephropathy (ND) is a microvascular complication of diabetes (DM) and the first cause of chronic kidney disease in our environment. In pathophysiology, the Angiotensin Aldosterone renin system (ARS) is one of the important mechanisms involved and the main therapeutic target. There is an increase in circulating, urinary and renal activity of the angiotensin converting enzyme (ACE)2 associated with increased albuminuria. Our group has dem...)
Jump to navigation Jump to search
Project Q3155555 in Spain
Language Label Description Also known as
English
No label defined
Project Q3155555 in Spain

    Statements

    0 references
    0 references
    48,250.0 Euro
    0 references
    96,500.0 Euro
    0 references
    50.0 percent
    0 references
    1 January 2016
    0 references
    30 September 2020
    0 references
    FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE NAVARRA
    0 references
    0 references

    42°49'6.42"N, 1°38'39.34"W
    0 references
    31201
    0 references
    La nefropatía diabética (ND) es una complicación microvascular de la diabetes (DM) y primera causa de enfermedad renal crónica en nuestro medio. En la fisiopatología, el Sistema renina Angiotensina Aldosterona (SRAA) es uno de los importantes mecanismos implicados y principal diana terapéutica. Existe un aumento de actividad circulante, urinaria y renal del enzima conversor de angiotensina (ECA)2 asociado al aumento de albuminuria. Nuestro grupo ha demostrado la importancia de la metaloproteinasa-10 (MMP-10) en el daño vascular, y en el grado de nefropatía en DM1. La vitamina D parece ser beneficiosa en ND por modulación de renina y efecto antiinflamatorio, asociado con algunas MMP. Hipótesis: En la DM2, la MMP-10 pueden tener un papel crucial en la fisiopatología de la ND especialmente por su potencial interacción con SRAA y vitamina D a partir de los cuales podría ser regulable. Objetivos: 1) Estudiar en pacientes con DM2 los niveles de MMP-10 en relación con actividad circulante de ECA2 y vitamina D y, su asociación con eventos cardiovasculares 2) Identificar la relación existente entre perfusión renal medida mediante resonancia magnética (Arterial Spin Labeling, ASL) y niveles de MMP-10 y ECA2. 3) Determinar el papel de la MMP-10 y ECA2 en ND utilizando ratones db/db con y sin bloqueo de SRAA. Métodos: 1) Clínico: Medición de MMP-10/TIMP-1, ECA2 y vitamina D en 203 pacientes DM2 y 60 controles sanos con seguimiento a 2 años de complicaciones macrovasculares. Estudio RM-ASL: 60 diabeticos y 60 sanos. 2) Experimental: Modelo murino db/db con y sin bloqueo de RAAS (losartán). Los resultados de este estudio permitirán establecer el papel de MMP-10 como nuevo biomarcador y diana terapeútica en la ND asociada a DM2. (Spanish)
    0 references
    Diabetic nephropathy (ND) is a microvascular complication of diabetes (DM) and the first cause of chronic kidney disease in our environment. In pathophysiology, the Angiotensin Aldosterone renin system (ARS) is one of the important mechanisms involved and the main therapeutic target. There is an increase in circulating, urinary and renal activity of the angiotensin converting enzyme (ACE)2 associated with increased albuminuria. Our group has demonstrated the importance of metalloproteinase-10 (MMP-10) in vascular damage, and in the degree of nephropathy in DM1. Vitamin D appears to be beneficial in ND by renin modulation and anti-inflammatory effect, associated with some MMPs. Scenario: In DM2, MMP-10 can play a crucial role in the pathophysiology of ND especially because of its potential interaction with SARS and vitamin D from which it could be adjustable. Objectives: 1) Study MMP-10 levels in relation to circulating activity of ACE2 and vitamin D in patients with DM2 and their association with cardiovascular events 2) Identify the relationship between renal infusion measured by magnetic resonance (Arterial Spin Labeling, ASL) and MMP-10 and ECA2 levels. 3) Determine the role of MMP-10 and ECA2 in ND using db/db mice with and without SRAA blocking. Methods: 1) Clinical: Measurement of MMP-10/TIMP-1, ECA2 and vitamin D in 203 DM2 patients and 60 healthy controls with follow-up to 2 years of macrovascular complications. RM-ASL study: 60 diabetics and 60 healthy. 2) Experimental: Murino model db/db with and without RAAS lock (losartan). The results of this study will make it possible to establish the role of MMP-10 as a new biomarker and therapeutic target in the ND associated with DM2. (English)
    12 October 2021
    0 references
    Pamplona/Iruña
    0 references

    Identifiers

    PI15_02111
    0 references